sched13ga012009.htm
 
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
 
 
 
Soligenix, Inc.
____________________________________________________________________________________
(Name of Issuer)
 
 
 
Common Stock, Par Value $0.001 per share
_____________________________________________________________________________________
(Title of Class of Securities)
 
 
 
258094101
_____________________________________________________________________________________
(CUSIP Number)
 
 
 
October 9, 2009
____________________________________________________________________________________
(Date of Event which Requires Filing of this Statement)
 
 
 
Check the appropriate box to designate the rule pursuant
 
to which this Schedule is filed:
 
 
 
o
 
Rule 13d-1(b)
 
x
 
Rule 13d-1(c)
 
o
 
Rule 13d-1(d)
 
 
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
 
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
_____________________________________________________________________________________
 
 
1
 
 
 
 
 
 
 
1.
 
Names of Reporting Persons.
 
I.R.S. Identification Nos. of above persons (entities only).
 
 
Biotex Pharma Investments, LLC
 
2.
 
Check the Appropriate Box if a Member of a Group (See Instructions)
 
 
(a)
 
 
(b)
 
 
3.
 
SEC Use Only
 
 
 
 
4.
 
Citizenship or Place of Organization
 
 
Delaware
 
 
 
5.
 
Sole Voting Power    17,395,000
 
 
 
Number of
Shares
Beneficially
 
6.
 
0
 
Owned by Each
Reporting
Person With:
 
7.
 
Sole Dispositive Power   17,395,000
 
 
 
8.
 
Shared Dispositive Power   0
 
 
 
9.
 
Aggregate Amount Beneficially Owned by Each Reporting Person    17,395,000
 
 
 
10.
 
Check box if the Aggregate Amount in Row (9) Excludes
 
Certain Shares (See Instructions)                                                       N/A                       
 
 
 
11.
 
Percent of Class Represented by Amount in Row (9)
 
 
9.38% (based on 185,501,158 shares of common stock outstanding as of October 5, 2009, as reported in the Issuer’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission on October 7, 2009).
 
 
 
12.
 
Type of Reporting Person (See Instructions)  00
 
 
 
_____________________________________________________________________________________
 
 
 
 
2
 
 
 
 
Item 1(a).
 
Name of Issuer:
 
 
 
Soligenix, Inc.
 
 
 
Item 1(b).
 
Address of Issuer’s Principal Executive Offices:
 
 
 
29 Emmons Drive, Suite C-10, Princeton, NJ 08540
 
 
Item 2(a).
 
Name of Person Filing:
 
 
 
This statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)
 
 
 
 
Biotex Pharma Investments, LLC
 
 
 
Item 2(b).
 
Address of Principal Business Office:
 
 
 
Biotex Pharma Investments, LLC
 
220 W. 42nd Street, 6th Floor
 
New York, NY 10036
 
 
 
Item 2(c).
 
Citizenship:
 
 
 
 
 
Biotex Pharma Investments, LLC is a Delaware limited liability company.
 
 
 
Item 2(d).
 
Title of Class of Securities:
 
 
 
Common Stock, par value $0.001 (the “Shares”)
 
 
 
Item 2(e).
 
CUSIP Number:
 
 
 
258094101
 
 
 
Item 3.
 
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a:
 
 
 
This Item 3 is not applicable
 
 
_____________________________________________________________________________________
 
 
3
 
 
Item 4.
 
Ownership:
 
 
 
(a)
 
Amount beneficially owned:
 
17,395,000
 
 
 
 
 
 
 
(b)
 
Percent of class:
 
9.38%
 
 
 
 
 
 
 
(c)
 
Number of shares as to which such person has:
 
 
 
 
 
(i)
 
sole power to vote or to direct the vote:
 
17,395,000
 
(ii)
 
shared power to vote or to direct the vote:
 
0
 
(iii)
 
sole power to dispose or to direct the disposition of:
 
17,395,000
 
(iv)
 
shared power to dispose or to direct the disposition of:
 
0
 
 
 
 
 
Item 5.
 
Ownership of Five Percent or Less of a Class:
 
 
 
Not Applicable
 
 
 
Item 6.
 
Ownership of More than Five Percent on Behalf of Another Person:
 
 
 
Not Applicable
 
 
 
Item 7.
 
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
 
 
 
Not Applicable
 
 
 
Item 8.
 
Identification and Classification of Members of the Group:
 
 
 
Not Applicable
 
 
 
Item 9.
 
Notice of Dissolution of Group:
 
 
 
Not Applicable
 
 
_____________________________________________________________________________________
 
 
 
4
 
 
 
 
 
Item 10.
 
Certification:
 
 
 
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 
 
 
SIGNATURE
 
 
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
 
Dated:  November 9, 2009
 
 
 
BIOTEX PHARMA INVESTMENTS, LLC
 
 
 
By:    /s/ Robert Kessler
Name:    Robert Kessler
Title:      Member
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5